Comparison of Response to the Concurrent Low Dose Daily Cisplatin Vs Weekly Cisplatin Vs Three Weekly Cisplatin with External Beam Radiotherapy in Carcinoma Cervix Patients of Stage IIB, IIIA & IIIB: A Prospective Study from Single Institution

International Journal of Medical Science And Diagnosis Research Pub Date : 2021-11-11 DOI:10.32553/ijmsdr.v5i11.871

A. Ubale, S. Chandra, S. Prasad, P. K. Singh

{"title":"Comparison of Response to the Concurrent Low Dose Daily Cisplatin Vs Weekly Cisplatin Vs Three Weekly Cisplatin with External Beam Radiotherapy in Carcinoma Cervix Patients of Stage IIB, IIIA & IIIB: A Prospective Study from Single Institution","authors":"A. Ubale, S. Chandra, S. Prasad, P. K. Singh","doi":"10.32553/ijmsdr.v5i11.871","DOIUrl":null,"url":null,"abstract":"Introduction: Cervical cancer continues to be a major public health problem affecting middle-aged women, particularly in less-resourced countries. External beam radiation therapy along with intra cavitary insertion has long been the treatment of choice for locally advanced (IIB-IVA) cervical cancer, but long-term successes are limited in terms of pelvic recurrence or distant metastasis. Outcome of low dose daily versus weekly versus three weekly Cisplatin concurrent with External beam radiotherapy in locally advanced cervical carcinoma was compared in this study. \nMethods: A prospective cross sectional study was carried out in J K cancer institute, Kanpur. Total 60 patients of cervical cancer were randomized into 3 arms. Arm I, Arm II and Arm III received External beam radiotherapy concurrent with either daily (8mg/m2), weekly (40 mg/m2) or three weekly (100 mg/m2) Cisplatin respectively. External beam radiotherapy was given with a dose of 50 Gy / 25 # / 5 week / 2 field or 4 field. Patients were evaluated weekly during treatment and afterwards up to 1year. Results: Most of the patients were from fourth and fifth decade, low socioeconomic strata and illiterate. Majority of the cases belong to squamous cell carcinoma (96.6%) and stage III B (55%). Objective response in arm I was 80.0%, in arm II was 75.0% and in arm III was 60.0% respectively. Statistically significant difference was noted between arm III and Arm I (80%Vs60% p<0.05). Results were better in arm I as compare to arm II but not statistically significant. (80%Vs75% P>0.05) \nConclusions: This study showed that response was better in ARM I as compared to ARM III and best results was seen with Cisplatin concurrent daily with radiation. \nKeywords: Cisplatin, concurrent chemotherapy, daily, weekly, three weekly, carcinoma cervix","PeriodicalId":14075,"journal":{"name":"International Journal of Medical Science And Diagnosis Research","volume":"9 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Medical Science And Diagnosis Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32553/ijmsdr.v5i11.871","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Cervical cancer continues to be a major public health problem affecting middle-aged women, particularly in less-resourced countries. External beam radiation therapy along with intra cavitary insertion has long been the treatment of choice for locally advanced (IIB-IVA) cervical cancer, but long-term successes are limited in terms of pelvic recurrence or distant metastasis. Outcome of low dose daily versus weekly versus three weekly Cisplatin concurrent with External beam radiotherapy in locally advanced cervical carcinoma was compared in this study. Methods: A prospective cross sectional study was carried out in J K cancer institute, Kanpur. Total 60 patients of cervical cancer were randomized into 3 arms. Arm I, Arm II and Arm III received External beam radiotherapy concurrent with either daily (8mg/m2), weekly (40 mg/m2) or three weekly (100 mg/m2) Cisplatin respectively. External beam radiotherapy was given with a dose of 50 Gy / 25 # / 5 week / 2 field or 4 field. Patients were evaluated weekly during treatment and afterwards up to 1year. Results: Most of the patients were from fourth and fifth decade, low socioeconomic strata and illiterate. Majority of the cases belong to squamous cell carcinoma (96.6%) and stage III B (55%). Objective response in arm I was 80.0%, in arm II was 75.0% and in arm III was 60.0% respectively. Statistically significant difference was noted between arm III and Arm I (80%Vs60% p<0.05). Results were better in arm I as compare to arm II but not statistically significant. (80%Vs75% P>0.05) Conclusions: This study showed that response was better in ARM I as compared to ARM III and best results was seen with Cisplatin concurrent daily with radiation. Keywords: Cisplatin, concurrent chemotherapy, daily, weekly, three weekly, carcinoma cervix

查看原文本刊更多论文

IIB期、IIIA期和IIIB期宫颈癌患者同时低剂量每日顺铂与每周顺铂与每周三次顺铂外束放疗的疗效比较:一项来自单一机构的前瞻性研究

引言:宫颈癌仍然是影响中年妇女的一个主要公共卫生问题，特别是在资源匮乏的国家。长期以来，外束放射治疗和腔内插入一直是局部晚期(IIB-IVA)宫颈癌的治疗选择，但就盆腔复发或远处转移而言，长期成功是有限的。本研究比较了低剂量每日、每周、每周三次顺铂联合外束放疗治疗局部晚期宫颈癌的疗效。方法:在坎普尔jk癌症研究所进行前瞻性横断面研究。60例宫颈癌患者随机分为3组。第1组、第2组和第3组分别接受外束放疗，同时使用每日(8mg/m2)、每周(40mg /m2)或每周3次(100mg /m2)顺铂。外束放疗剂量为50 Gy / 25 # / 5周/ 2场或4场。治疗期间每周对患者进行评估，之后持续1年。结果:患者多为40 ~ 50岁，低社会经济阶层，文盲。大多数病例属于鳞状细胞癌(96.6%)和III期B(55%)。I组客观有效率为80.0%，II组为75.0%，III组为60.0%。结论:本研究显示，与arm III相比，arm I的疗效更好，顺铂每日同步放疗的效果最好。关键词:顺铂，同期化疗，每日，每周，三周，宫颈癌

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Medical Science And Diagnosis Research

自引率

0.00%

发文量